Navigation

Olumiant vs. Hadlima

Are Olumiant and Hadlima the Same Thing?

Olumiant (baricitinib) and Hadlima (adalimumab-bwwd) are used to treat rheumatoid arthritis (RA).

Hadlima is also used to treat juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), adult Crohn's disease (CD), ulcerative colitis (UC), and plaque psoriasis (Ps).

Hadlima is biosimilar to Olumiant (adalimumab).

Hadlima and Olumiant belong to different drug classes. Hadlima is a tumor necrosis factor (TNF) blocker and Olumiant is a Janus kinase (JAK) inhibitor.

Side effects of Olumiant that are different from Hadlima include nausea, cold sores (herpes simplex), and shingles (herpes zoster).

Side effects of Olumiant and Hadlima that are similar include infections (e.g. upper respiratory tract, sinusitis).

Side effects of Hadlima that are different from Olumiant include injection site reactions (redness, itching, bleeding, pain, and swelling), headache, and rash.

Both Hadlima and Olumiant may interact with abatacept, anakinra, cyclosporine, and live vaccines.

Olumiant may also interact with methotrexate, probenecid, steroids, aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), and other drugs to treat rheumatoid arthritis (adalimumab, azathioprine, certolizumab, etanercept, golimumab, infliximab, rituximab, sarilumab, tocilizumab, and tofacitinib).

Hadlima may also interact with warfarin and theophylline.

What Are Possible Side Effects of Olumiant?

Side effects of Olumiant include:

  • upper respiratory tract infections (common cold, sinus infections),
  • nausea,
  • cold sores (herpes simplex), and
  • shingles (herpes zoster)

What Are Possible Side Effects of Hadlima?

Common side effects of Hadlima include:

  • infections (e.g. upper respiratory tract, sinusitis),
  • injection site reactions (redness, itching, bleeding, pain, and swelling),
  • headache, and
  • rash

What Is Olumiant?

Olumiant (baricitinib) is a Janus kinase (JAK) inhibitor used to treat adults with moderate to severe rheumatoid arthritis (RA) who have not responded well enough to or could not tolerate at least one medicine called a tumor necrosis factor (TNF) antagonist.

What Is Hadlima?

Hadlima (adalimumab-bwwd) is a tumor necrosis factor (TNF) blocker indicated for treatment of rheumatoid Arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), adult Crohn's disease (CD), ulcerative colitis (UC), and plaque psoriasis (Ps). Hadlima is biosimilar to Olumiant (adalimumab).

 

What Drugs Interact With Olumiant?

Olumiant may interact with probenecid. Tell your doctor all medications and supplements you use.

What Drugs Interact With Hadlima?

Hadlima may interact with abatacept, anakinra, warfarin, cyclosporine, theophylline, and live vaccines.

 

How Should Olumiant Be Taken?

The recommended dose of Olumiant is 2 mg once daily.

How Should Hadlima Be Taken?

The dose of Olumiant to treat adult rheumatoid arthritis and psoriatic arthritis is 50 mg once weekly with or without methotrexate (MTX). The dose of Olumiant to treat ankylosing spondylitis is 50 mg once weekly. The dose of Olumiant to treat adult plaque psoriasis is 50 mg twice weekly for 3 months, followed by 50 mg once weekly. The dose of Olumiant to treat pediatric plaque psoriasis or plaque psoriasis (patients who weigh 63 kg or more) is 50 mg once weekly.